ClinicalTrials.Veeva

Menu

Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

Shire logo

Shire

Status and phase

Completed
Phase 2

Conditions

Attention Deficit Disorder With Hyperactivity

Treatments

Drug: Placebo
Drug: SPD503 (Guanfacine HCl)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00150592
SPD503-206

Details and patient eligibility

About

The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.

Enrollment

182 patients

Sex

All

Ages

6 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects with a primary diagnosis of ADHD
  • Minimum baseline visit ADHD-RS-IV score of 24 and a baseline CGI-S score =>4
  • Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements
  • Subject weighs > 55 lbs and is not morbidly overweight

Exclusion criteria

  • Subject has a comorbid psychiatric diagnosis (except ODD) with significant symptoms such as any severe comorbid Axis II disorders or severe Axis I disorders
  • Subject has a history of seizure disorder
  • Subject has any specific cardiac condition or family history of significant cardiac condition
  • Subject is pregnant, lactating or within six month post-partum

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

182 participants in 2 patient groups, including a placebo group

SPD503 (Guanfacine HCl)
Experimental group
Treatment:
Drug: SPD503 (Guanfacine HCl)
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems